Advertisement
Canada markets close in 4 hours 3 minutes

  • S&P/TSX

    21,830.08
    +121.64 (+0.56%)
     

  • S&P 500

    4,986.71
    -24.41 (-0.49%)
     

  • DOW

    37,925.23
    +149.85 (+0.40%)
     

  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    82.94
    +0.21 (+0.25%)
     

  • Bitcoin CAD

    88,623.67
    +1,313.60 (+1.50%)
     

  • CMC Crypto 200

    1,387.36
    +74.74 (+6.04%)
     

  • GOLD FUTURES

    2,407.50
    +9.50 (+0.40%)
     

  • RUSSELL 2000

    1,947.28
    +4.32 (+0.22%)
     

  • 10-Yr Bond

    4.6060
    -0.0410 (-0.88%)
     

  • NASDAQ

    15,405.26
    -196.24 (-1.26%)
     

  • VOLATILITY

    18.50
    +0.50 (+2.77%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6826
    +0.0005 (+0.07%)
     
MARKETS LIVE BLOG:

STOCKS TRADE MIXED AFTER ISRAEL STRIKE-FUELLED TUMBLE

Apple pulls WhatsApp and Threads from China App Store

SPPI LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Spectrum Pharmaceuticals, Inc.

Newsfile Corp.
·1 min read

New York, New York--(Newsfile Corp. - October 28, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum") between December 27, 2018 and August 5, 2021.

If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?prid=20733&wire=5

Allegations against SPPI include that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

ADVERTISEMENT

If you suffered a loss in Spectrum you have until November 1, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101137